97 related articles for article (PubMed ID: 3056425)
41. Synthesis and immunostimulating properties of lipophilic ester and ether muramyl peptide derivatives.
Merhi G; Coleman AW; Devissaguet JP; Barratt GM
J Med Chem; 1996 Oct; 39(22):4483-8. PubMed ID: 8893843
[TBL] [Abstract][Full Text] [Related]
42. Muramyl peptides: immunomodulators, sleep factors, and vitamins.
Adam A; Lederer E
Med Res Rev; 1984; 4(2):111-52. PubMed ID: 6374337
[No Abstract] [Full Text] [Related]
43. [The characteristics of the action of a chemical immunomodulator in a latent viral infection].
Kalenderov AK; Semenova IB
Zh Mikrobiol Epidemiol Immunobiol; 1993; (6):87-8. PubMed ID: 8079590
[No Abstract] [Full Text] [Related]
44. Muramyl-peptide/gastrin conjugates as potential immunogens.
Moroder L; Dufresne M; Göhring W; Wünsch E; Leidinger E; Gemeiner M
Biol Chem Hoppe Seyler; 1989 Nov; 370(11):1209-14. PubMed ID: 2610937
[TBL] [Abstract][Full Text] [Related]
45. Development of an emulsion-based muramyl dipeptide adjuvant formulation for vaccines.
Lidgate DM; Byars NE
Pharm Biotechnol; 1995; 6():313-24. PubMed ID: 7551223
[No Abstract] [Full Text] [Related]
46. [The principles in correcting secondary immunodeficiencies by using 2 immunomodulators of differing character--purified staphylococcal anatoxin and likopid].
Semenova IB
Zh Mikrobiol Epidemiol Immunobiol; 1998; (1):100-4. PubMed ID: 9532703
[No Abstract] [Full Text] [Related]
47. Synthesis of N-(2-acetamido-2,3-dideoxy-D-glucopyranos-3-yl)glycyl-L-alanyl-D -isoglutamine analogues of muramyl dipeptide.
Calvo-Mateo A; De Las Heras FG
Carbohydr Res; 1986 Nov; 155():266-71. PubMed ID: 3791300
[No Abstract] [Full Text] [Related]
48. Radioimmunoassay for N alpha-(N-acetylmuramyl-alanyl-D-isoglutaminyl)-N epsilon-stearyl-lysine.
Masayasu H; Ono K; Takegoshi T
Chem Pharm Bull (Tokyo); 1984 Oct; 32(10):4124-9. PubMed ID: 6529806
[No Abstract] [Full Text] [Related]
49. Muramyl dipeptides: prospect for cancer treatments and immunostimulation.
Kotani S; Azuma I; Takada H; Tsujimoto M; Yamamura Y
Adv Exp Med Biol; 1983; 166():117-58. PubMed ID: 6650278
[TBL] [Abstract][Full Text] [Related]
50. Immune boosters. Murabutide--debut of a new immune booster?
TreatmentUpdate; 2003; 15(4):3. PubMed ID: 17216851
[No Abstract] [Full Text] [Related]
51. GMDP and psoriasis.
Bhushan M; McElhone K; Griffiths CE
Lancet; 1998 Dec; 352(9143):1857. PubMed ID: 9851410
[No Abstract] [Full Text] [Related]
52. [The effect of the immunomodulator glucosaminylmuramyl dipeptide on hematopoiesis in mice with experimental cytopenia].
Andrianova IE; Filimonova GI; Andronova TM
Radiobiologiia; 1992; 32(4):566-70. PubMed ID: 1410295
[TBL] [Abstract][Full Text] [Related]
53. Comparative susceptibility of DA, LEW, and LEW.1AV1 rats to arthritis induced with different arthritogens: mineral oil, mycobacteria, muramyl dipeptide, avridine and rat collagen type II.
Lorentzen JC; Klareskog L
Transplant Proc; 1997 May; 29(3):1692-3. PubMed ID: 9142235
[No Abstract] [Full Text] [Related]
54. Macrophage-produced muramyl peptide contaminants as adjuvants in cell-transfer experiments.
Westall FC; Root-Bernstein RS
Mol Immunol; 1985 Apr; 22(4):505-6. PubMed ID: 4033669
[No Abstract] [Full Text] [Related]
55. Biological response modifiers.
Clark JW
Cancer Chemother Biol Response Modif; 1991; 12():193-212. PubMed ID: 1931443
[No Abstract] [Full Text] [Related]
56. [The clinical economic analysis of application of immune correcting preparations to prevent respiratory infections and their complications in frequently ill children of early school age].
Maiorov RV; Derbenov DP
Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2014; (6):23-6. PubMed ID: 25799746
[TBL] [Abstract][Full Text] [Related]
57. "Meshed-Bag Gathered-Bunch" method for solid-phase synthesis of small molecular diverse compounds.
Zhang SD; Liu G; Xia SQ; Wu P; Zhang L
J Comb Chem; 2002; 4(2):131-7. PubMed ID: 11886287
[TBL] [Abstract][Full Text] [Related]
58. Adjuvants of immunity.
Chedid L
Ann Inst Pasteur Immunol (1985); 1985; 136D(3):283-91. PubMed ID: 3913381
[No Abstract] [Full Text] [Related]
59. Validation of a first-generation Epstein-Barr virus vaccine preparation suitable for human use.
Morgan AJ; Allison AC; Finerty S; Scullion FT; Byars NE; Epstein MA
J Med Virol; 1989 Sep; 29(1):74-8. PubMed ID: 2555448
[TBL] [Abstract][Full Text] [Related]
60. Pericholangitis in a rabbit colitis model induced by injection of muramyl dipeptide emulsified with a long-chain fatty acid.
Kuroe K; Haga Y; Funakoshi O; Kanazawa K; Mizuki I; Yoshida Y
J Gastroenterol; 1996 Jun; 31(3):347-52. PubMed ID: 8726825
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
